Engrail Therapeutics is a clinical-stage biopharmaceutical company founded in 2019, focused on precision neuroscience. It develops precision-targeted small-molecule therapeutics (pipeline: ENX-102, ENX-104, ENX-203, ENX-205) for nervous-system disorders, combining internal discovery with strategic partnerships.
Surfaced as a portfolio company of norwest-venture-partners and added to the API Evangelist network. Engrail publishes no public developer/API surface, so this profile carries company identity plus a domain-security probe only.
Website: https://engrail.com Backed by: norwest-venture-partners